Etanercept in adult patients with early onset ankylosing spondylitis.
J Rheumatol
; 33(8): 1634-6, 2006 Aug.
Article
in En
| MEDLINE
| ID: mdl-16881118
ABSTRACT
OBJECTIVE:
To determine whether twice-weekly subcutaneous etanercept improves the signs and symptoms of adult patients with early onset ankylosing spondylitis (AS).METHODS:
A retrospective analysis was performed on a subgroup of patients with AS with onset < 18 years of age from a multicenter, double-blind, placebo-controlled, randomized study of etanercept in the treatment of patients with AS. Twenty patients met criteria and are presented.RESULTS:
As early as week four, 5/9 (56%) patients who received etanercept achieved an Assessments in Ankylosing Spondylitis 20% response (ASAS 20) versus only 1/11 (9%) of those who received placebo (p = 0.032). The observed ASAS 20 response continued through week 24, with 6/9 (66%) patients receiving etanercept responding, versus 2/11 of patients receiving placebo (p = 0.025).CONCLUSION:
Etanercept improves signs and symptoms of early onset AS in adult patients for at least 24 weeks.
Search on Google
Database:
MEDLINE
Main subject:
Spondylitis, Ankylosing
/
Immunoglobulin G
/
Tumor Necrosis Factor-alpha
/
Receptors, Tumor Necrosis Factor
/
Antirheumatic Agents
Type of study:
Observational_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Year:
2006
Type:
Article